Janus Henderson Group PLC Medicenna Therapeutics Corp. Transaction History

Janus Henderson Group PLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 16, 2021	SELL	$2.97 - $4.28 $1.57 Million - $2.27 Million	-529,325 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$3.5 - $4.56 $1.85 Million - $2.41 Million	529,325 New	529,325 $2.15 Million

863K

Ticker MDNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,637,504
Market Cap $21.6M
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.